2022鄂尔多斯在职硕士备考-MBA英语第二套模拟题例文.docx

2022鄂尔多斯在职硕士备考-MBA英语第二套模拟题4 方式二：扫描二维码 招警题库军人考试题库三支一扶题库 鄂尔多斯在职硕士 内蒙公务员 事业单位 老师聘请 银行聘请 农信社 国企 公选 国家公务员 医疗卫生 特岗老师 老师资格 选调生 招警 更多 在职硕士 报考资讯 备考资料 考试题库 院校招生 19课堂 面授课程 网络课程 图书教材 热点举荐  考研阅读资料  考研报考指导  考研考试题库 您现在的位置：首页 >在职硕士 > 考试题库 > 2022鄂尔多斯在职硕士备考-MBA英语其次套模拟题4 2021-10-20 09:30:34| 来源：鄂尔多斯中公教化 共享到： 0 Text 3 In 2022. a federal judge shook America's biotech industry to its core. Companies had won patents for isolated DNA for decades-by 2022 some 20% of human genes were parented. But in March 2022 a judge ruled that genes were unpatentable. Executives were violently agitated. The Biotechnology Industry Organisation (BIO)， a trade group， assured members that this was just a preliminary step in a longer battle.On July 29th they were relieved， at least temporarily. A federal appeals court overturned the prior decision， ruling that Myriad Genetics could indeed holb patents to two genss that help forecast a woman's risk of breast cancer. The chief executive of Myriad， a company in Utah，said the ruling was a blessing to firms and patients alike.But as companies continue their attempts at personalised medicine， the courts will remain rather busy. The Myriad case itself is probably not over Critics make three main arguments against gene patents： a gene is a product of nature， so it may not be patented; gene patents suppress innovation rather than reward it; and patents' monopolies restrict access to genetic tests such as Myriad's. A growing number seem to agree.Last year a federal task-force urged reform for patents related to genetic tests. In October the Department of Justice filed a brief in the Myriad case， arguing that an isolated DNA molecule is no less a product of nature. than are cotton fibres that have been separated from cotton seeds.Despite the appeals court's decision， big questions remain unanswered. For example， it is unclear whether the sequencing of a whole genome violates the patents of indivi dual genes within it. The case may yet reach the Supreme Court.AS the industry advances ,however,other suits may have an even greater panies are unlikely to file many more patents for human DNA molecules-most are already patented or in the public domain .firms are now studying how genes intcract,looking for correlations that might be used to determine the causes of disease or predict a drug’s efficacy,companies are eager to win patents for connecting the dits’,expaains hans sauer,alawyer for the BIO.Their success may be determined by a suit related to this issue, brought by the Mayo Clinic, which the Supreme Court will hear in its next term. The BIO rtcently held a convention which included seddions to coach lawyers on the shifting landscape for patents. Each meeting was packed.31.it canbe learned from paragraph I that the biotech companies would like-A.their executives to be active B.judges to rule out gene patentingC.genes to be patcntablc D.the BIO to issue a warning32.those who are against gene patents believe that-A.genetic tests are not reliable B.only man-made products are patentableC.patents on genes depend much on innovatiaon D.courts should restrict access to gene tic tests33.according to hans sauer ,companies are eager to win patents for-A.establishing disease comelations B.discovering gene interactionsC.drawing pictures of genes D.identifying human DNA34.By saying each meeting was packed(line4,para6)the author means that -A.the supreme court was authoritative B.the BIO was a powerful organizationC.gene patenting was a great concern D.lawyers were keen to attend conventiongs35.generally speaking ,the author’s attitude toward gene patenting is-A.criticalB.supportive C.scornful D.objective参考答案：TEXT3：31.C 32.B 33.A 34.D 35.D 注：本站稿件未经许可不得转载，转载请保留出处及源文件地址。 (责任编辑：wyxeeds) 关键词阅读 上一篇：2022鄂尔多斯在职硕士备考-MBA英语其次套模拟题3 下一篇：2022鄂尔多斯在职硕士备考-MBA英语其次套模拟题5 快速访问手机站